Abstract

Sildenafil is used as off-label medication in pulmonary hypertension (PH) secondary to valvular heart disease (VHD). To date, limited investigations and guidelines are available to recommend the usefulness of sildenafil in this group of patients. Previously, published systematic review only reported the efficacy of sildenafil for PH with VHD in preoperative conditions.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.